RD 201
Alternative Names: RD-201Latest Information Update: 28 Sep 2023
At a glance
- Originator Nanjing IASO Biotherapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastric cancer; Lymphoma; Nasopharyngeal cancer
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for research development in Gastric-cancer in China (Parenteral)
- 28 Sep 2023 No recent reports of development identified for research development in Lymphoma in China (Parenteral)
- 28 Sep 2023 No recent reports of development identified for research development in Nasopharyngeal-cancer in China (Parenteral)